Addendum

Nivolumab (NSCLC, neoadjuvant) – Addendum to Project A23-74

Report documents

Indication:

Neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%

Result of dossier assessment:

Unchanged after addendum: added benefit not proven

2024-02-01 A G-BA decision was published.

Project no.: A23-131
Commission: Commission awarded on 12.12.2023 by the Federal Joint Committee (GBA).
Report type: Addendum
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI: https://dx.doi.org/10.60584/A23-131

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.